Home › Calculator › INCPF Dividend Calculator 2026
INCPF Dividend DRIP Calculator 2026
129.03% YieldHealthcareInnoCare Pharma Limited · OTC
Price: $1.55 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When INCPF pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your INCPF snowball 📈
$10,000 in INCPF → $30.24M in 10 years · $3,171.33/month
About InnoCare Pharma Limited (INCPF) — Dividend Analysis 2026
InnoCare Pharma Limited is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments, primarily targeting cancer and autoimmune disorders. A key product in their portfolio is Orelabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor. This therapy targets various relapsed or refractory blood cancers, including chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom's macroglobulinemia, marginal zone lymphoma, diffuse large B-cell lymphoma (MCD subtype), central nervous system lymphoma, and is also being explored in combination with MIL-62. Furthermore, Orelabrutinib is under investigation for a range of autoimmune conditions such as systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. The company's broader pipeline features several investigational candidates in various clinical trial stages. For example, ICP-192, a pan-FGFR inhibitor, is currently in Phase I/II trials for solid tumors like cholangiocarcinoma and head and neck cancer. Compounds in Phase I clinical trials include ICP-723, a pan-TRK inhibitor addressing cancers with neurotrophic tyrosine receptor kinase fusions; ICP-332, a novel tyrosine kinase 2 (TYK2) inhibitor for autoimmune diseases; and ICP-B02, a bispecific antibody targeting lymphoma. Further preclinical and early-stage assets encompass ICP-189, ICP-915, and ICP-B03 for solid tumors; ICP-033 for liver, renal cell, colorectal, and other solid tumors; ICP-488 for autoimmune diseases; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody for various cancers; and ICP-248 and ICP-490, both focusing on hematological conditions, with ICP-490 also extending to autoimmune diseases. Additionally, InnoCare offers Tafasitamab (marketed as ICP-B04), indicated for the treatment of diffuse large B-cell lymphoma and other hematological malignancies. Established in 2015, InnoCare Pharma Limited maintains its headquarters in Beijing, China.
Compare INCPF with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full INCPF DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open INCPF position with:
🌍 INCPF Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold INCPF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 129.03% | 126.23% | $12,903 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 109.68% | 106.88% | $10,968 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 103.22% | 100.42% | $10,322 / yr |
| 🇬🇧 UK ISA | 0% | 129.03% | 126.23% | $12,903 / yr |
| 🇬🇧 UK Taxable | 8.75% | 117.74% | 114.94% | $11,774 / yr |
| 🇨🇦 TFSA | 0% | 129.03% | 126.23% | $12,903 / yr |
| 🇨🇦 CA Taxable | 25% | 96.77% | 93.97% | $9,677 / yr |
| 🇦🇺 Super (pension) | 15% | 109.68% | 106.88% | $10,968 / yr |
| 🇦🇺 AU Taxable | 30% | 90.32% | 87.52% | $9,032 / yr |
| 🇩🇪 DE Taxable | 26.375% | 95.00% | 92.20% | $9,500 / yr |
| 🇫🇷 FR Taxable | 30% | 90.32% | 87.52% | $9,032 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 INCPF Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 INCPF Dividend Payment Schedule
INCPF pays quarterly — 4 times per year. Next ex-div: TBD.
📊 INCPF vs Healthcare Benchmarks
How INCPF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for INCPF sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ INCPF Insider Activity
No recent SEC filings reported in the last 90 days.Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the INCPF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
InnoCare Pharma Limited (INCPF) is currently trading at $1.55, trading near its 52-week low. The current dividend yield is 129.03% based on an annual payout of $2.00 per share.
INCPF (InnoCare Pharma Limited) — 129.03% Dividend Yield Analysis
InnoCare Pharma Limited (INCPF) is a healthcare stock currently trading at $1.55 with a dividend yield of 129.03%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (129.03%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.